SCHEMBL7735552

SCHEMBL7735552

CCCCn1ccc(-c2cc(Br)ccc2OC)c(C(=O)O)c1=O

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 3/20 0.40
ACHE P22303 1/20 0.40
HTR4 Q13639 1/20 0.40
TNF P01375 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
GRK6 P43250 1/20 0.39
CNR2 P34972 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
MAPK1 P28482 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
KDM4E B2RXH2 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 3/20 0.36
HTT P42858 1/20 0.36
MAPT P10636 1/20 0.36
PPARA Q07869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7736093 0.88 KDM4E (0.47) BRD9TNFMEN1KMT2AKDM4E
SCHEMBL7736063 0.87 ALDH1A1 (0.42) BRD9TNFMEN1KMT2ACNR2
SCHEMBL7737859 0.85 MEN1 (0.45) TNFMEN1KMT2ACNR2KDM4E
SCHEMBL7726010 0.81 TOP1 (0.41) MEN1KMT2ASMN1; SMN2KDM4EHSD17B10
SCHEMBL7725865 0.80 MAPT (0.44) BRD9MEN1KMT2ASMN1; SMN2HDAC3
SCHEMBL7725862 0.79 BRD4 (0.39) MEN1KMT2ACNR2SMN1; SMN2MAPK1
SCHEMBL7735825 0.76 GFER (0.48) MEN1KMT2ASMN1; SMN2HDAC1HDAC6
SCHEMBL7726041 0.76 LPAR1 (0.53)
SCHEMBL7734365 0.75 ICMT (0.45) TNFMEN1KMT2ACNR2HDAC6
SCHEMBL7735824 0.75 GRM2 (0.49) BRD9KMT2ACNR2MAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452008-B2 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-17 US disclosed
US-20010051732-A1 Pyridone derivatives and process for preparing the same SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2001-12-13 US disclosed
US-6300500-B1 Preparation of pyridone derivatives using phthalimido containing starting material SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-10-09 US disclosed
EP-1086948-A1 PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051732-A1 Pyridone derivatives and process for preparing the same HK1, HPD, ALK BRD9 1513/4885ACHE 3922/4885HTR4 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.